SRR934988
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.493
- MYC_TARGETS_V1+0.459
- NOTCH_SIGNALING+0.458
- WNT_BETA_CATENIN_SIGNALING+0.439
- G2M_CHECKPOINT+0.415
- TGF_BETA_SIGNALING+0.413
- E2F_TARGETS+0.375
- UNFOLDED_PROTEIN_RESPONSE+0.339
- MITOTIC_SPINDLE+0.336
- DNA_REPAIR+0.312
Top 10 suppressed
- KRAS_SIGNALING_DN-0.411
- ESTROGEN_RESPONSE_LATE-0.308
- PANCREAS_BETA_CELLS-0.303
- SPERMATOGENESIS-0.286
- FATTY_ACID_METABOLISM-0.270
- XENOBIOTIC_METABOLISM-0.254
- CHOLESTEROL_HOMEOSTASIS-0.230
- BILE_ACID_METABOLISM-0.202
- OXIDATIVE_PHOSPHORYLATION-0.198
- HEME_METABOLISM-0.194
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934900 | — | — | 0.859 |
| 2 | 1AF24109-5FE4-4868-ADB9-5DFDB57BCA0F | — | — | 0.856 |
| 3 | 6B66F14C-7616-4DEC-A604-2168DBA50A1B | — | — | 0.851 |
| 4 | BB2A06D9-AF9B-4BF6-8EEC-8F53BD5536B0 | — | — | 0.849 |
| 5 | B2D8ED43-A698-4165-9A96-0ADEEFDA29ED | — | — | 0.840 |
| 6 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.839 |
| 7 | SRR934863 | — | — | 0.837 |
| 8 | 3DA19761-6FF3-4E8C-AA0F-C04CE2CE7037 | — | — | 0.836 |
| 9 | 76B4C53E-F764-412D-B238-E01F65CE09C8 | — | — | 0.832 |
| 10 | 9CD6C527-4E98-427F-9770-7155A1C6CB70 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.493 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.459 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.458 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.439 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.415 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.413 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.375 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.339 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.336 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.312 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.283 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.272 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.167 | Inavolisib | — uncovered |
| APOPTOSIS | 0.126 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.089 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.080 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.072 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.064 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.062 | Remibrutinib | — uncovered |